Home
/
SUTRO BIOPHARMA, INC.
/
Financials
/
Quarterly
SUTRO BIOPHARMA, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that SUTRO BIOPHARMA, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$7.84M
Nov 14, 2018
Q3
2018
Sep 30, 2017
$17.50M
Nov 14, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$9.69M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$63.75M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$17.40M
May 8, 2025
Q3
2025
Sep 30, 2024
$8.52M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$25.71M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$13.01M
May 8, 2025
Q3
2024
Sep 30, 2023
$16.92M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$10.41M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$12.67M
May 13, 2024
Q3
2023
Sep 30, 2022
$25.15M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$28.10M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$5.90M
May 15, 2023
Q3
2022
Sep 30, 2021
$8.52M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$28.05M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$14.66M
May 9, 2022
Q3
2021
Sep 30, 2020
$17.82M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$9.47M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$7.15M
May 7, 2021
Q3
2020
Sep 30, 2019
$12.28M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$10.53M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($56.86M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($11.50M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($11.50M)
Aug 7, 2025
Q2
2025
Mar 31, 2025
($75.97M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($75.97M)
May 8, 2025
Q3
2025
Mar 31, 2025
($75.97M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($48.79M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($48.02M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($48.02M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($58.21M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($58.21M)
May 8, 2025
Q2
2025
Mar 31, 2024
($58.21M)
Aug 7, 2025
Q3
2024
Sep 30, 2023
($49.28M)
Nov 13, 2024
Q3
2024
Jun 30, 2023
($38.52M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($38.52M)
Aug 13, 2024
Q2
2024
Mar 31, 2023
($50.05M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($50.05M)
May 13, 2024
Q3
2024
Mar 31, 2023
($50.05M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($19.49M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($26.01M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($48.46M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($3.35M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($68.51M)
May 8, 2025
Q3
2025
Sep 30, 2024
($67.92M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($48.69M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($56.59M)
May 8, 2025
Q3
2024
Sep 30, 2023
($44.01M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($46.18M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($42.24M)
May 13, 2024
Q3
2023
Sep 30, 2022
($21.21M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($19.38M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($39.13M)
May 15, 2023
Q3
2022
Sep 30, 2021
($34.67M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($9.81M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($19.01M)
May 9, 2022
Q3
2021
Sep 30, 2020
($10.62M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($16.42M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($19.18M)
May 7, 2021
Q3
2020
Sep 30, 2019
($12.74M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($13.69M)
Aug 6, 2020